Home
>
US Stocks
>
Immunic Inc
Immunic Inc
IMUX

Immunic Inc

$8.687.26%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
8.3
Today Low/High
8.3 / 8.7
52 Week Low/High
$7.69 / $28.21
Market Cap
$253.04M

Company Details

Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. Immunic is developing three small molecule products: its lead development program, IMU-838, is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function. Immunic announced positive results from its phase 2 EMPhASIS trial of IMU-838 in patients with relapsing-remitting multiple sclerosis, reporting achievement of both primary and key secondary endpoints with high statistical significance. IMU-838 is also in phase 2 clinical development for ulcerative colitis and COVID-19, with an additional phase 2 trial considered in Crohn's disease. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is ongoing at the Mayo Clinic.
Organisation
Immunic Inc
Headquaters
Martinsried, Bayern, Germany
Employees
28
Industry
Pharmaceuticals: Major
CEO
Daniel Vitt

Discover more

Frequently Asked Questions

What is Immunic Inc share price today

Can Indians buy Immunic Inc shares?

How can I buy Immunic Inc shares from India?

Can Fractional shares of Immunic Inc be purchased?

What are the documents required to start investing in Immunic Inc stocks?

We are a SEBI registered investement advisor